ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemotherapy (NAC) enables tumor downstaging and assessment of response in early breast cancer (EBC). Pathological complete response (pCR) predicts favorable outcomes, but patients with residual disease are heterogeneous, and the prognostic value of residual tumor biology remains incompletely defined.
methodsWe retrospectively analyzed 586 patients with EBC treated with NAC between 2000 and 2021. Baseline clinical, pathological, and treatment-related variables-including residual disease characteristics-were collected. The primary endpoints were pCR and long-term outcomes. Event-free survival (EFS), relapse-free survival (RFS), and overall survival (OS) were estimated using Kaplan-Meier curves and compared with log-rank tests. Multivariable logistic and Cox regression identified independent predictors of pCR and survival.
resultsOverall, 36.3% of patients achieved pCR, highest in HER2-positive (48.6%) and triple-negative tumors (45%). HER2-low/negative status, HR positivity, higher T stage, and lower Ki-67 independently reduced the likelihood of pCR. At a median follow-up of 88 months, patients achieving pCR had superior 7-year outcomes (EFS 86.5% vs 71.6%, RFS 91.1% vs 74.7%, OS 94.9% vs 81.7%; all p < 0.001). Among patients with residual disease, higher nodal burden (ypN2), high post-treatment Ki-67 (> 20%), residual HER2 positivity, and residual Hormone receptor (HR) negativity were independent predictors of poorer outcomes. No baseline or residual characteristics independently affected survival in patients achieving pCR.
conclusionpCR strongly predicts long-term outcomes, particularly in aggressive subtypes. Among patients with residual disease, higher nodal burden (ypN2), high post-treatment Ki-67 (> 20%), residual HR negativity, and residual HER2 positivity were independent predictors of poorer outcomes, supporting biologically informed risk stratification beyond pCR.
Indexed as
Identifiers
42560581What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.